A study conducted in several countries and centres to compare the efficacy and safety of an 8 week treatment of patients with high blood pressure with aliskiren 300mg given once daily in fasted state compared to fed state

Registry ID
EUCTR2011-005297-36
Source registry
EUCTR
Status
Completed
Phase
PHASE4
Sponsor
Novartis Farmaceutica SA
Start date
2012-02-23
Last update
2026-08-16

Conditions

Summary

To evaluate the efficacy of oral aliskiren 300 mg given once daily in reduction of mean 24 hour ambulatory systolic blood pressure (maSBP) from baseline to end of 8 week treatment under light meal (fed) versus fasted conditions in patients with mild to moderate hypertension.

Locations

View on source registry